Replies to post #68335 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Clearly Edelman’s team must have evaluated the EMA issue and felt that it has a solid chance.

[cdiddy01]

While it's exciting he's involved, reality is they spent 3 million dollars out of a 3 billion dollar fund to take a stake in this company. He bought in at the absolute ground floor. I'd like to know how much he's truly risking and how much weight people will actually put on this. I hope he buys more.

The company needs cash and needs it quickly, that's reality.

[tx_farmer]

Is Edelman truly the "best in the world"? I have never heard of him but that does not say much. If he bought at $2 then he is already down 10%+. Some pertinent catalyst are a long ways away, so what is he seeing that the rest of us are missing?

[HereToFightScams]

So the best doctors in their field work fo wall street, not on patients? I can't imagine a more idiotic post.

[Batermere]

So “THE BIOTECH INVESTMENT GURU” equivalent of Warren Buffett bought $3 million worth of ADXS at fire sale prices and if it goes to $3.50-4 he doubles his money? That does not make him the “WORLD’S BEST BIOTECH INVESTOR”. Most anyone would look at the risk vs reward at that entry price (lucky guy, I wish my DCA was $1.75-2) and pull the trigger just like he did. And he doesn’t need a team of MDs to advise him on it either. LOL. I think 99.9% of Biotech investor’s out there could have/would have done the very same thing considering ADXS’s promising pipeline and P3 status. BTW, $3 Million out of $3 Billion is .001%. That means 1/1000th of his overall portfolio is invested in ADXS. That is pretty much peanuts and inconsequential. If he increases that stake substantially to over 5% it might actually be a strong vote of confidence. Until then, this entire Edelman/Perspective Life Sciences purchase is a big MEH. We need A LOT MORE investors that believe in this company, both retail Main St Joe’s and Tutes, to buy into ADXS and get this dog out of “POS Purgatory”. Right now this is a Biotech Boondoggle firmly stuck below $2. The cash will run out in a few months. We can’t make it to an EMA Decision a year from now without a large cash infusion in the next several months. That is the “Elephant in Berlin’s CEO Room”. It needs to be addressed and fast. I hope he has what it takes to pull it off and be a hero. The 3 CEOs that preceded him were complete BUSTS.